General Information:

Id: 5,011
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
BTO:0000133 blood serum
article
Reference: Altmaier E et al.(2014) Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism Eur. J. Epidemiol. 29: 325-336 [PMID: 24816436]

Interaction Information:

Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49429

drug/chemical compound

Beta blocker

increases_quantity of

drug/chemical compound

Pyroglutamine

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49432

drug/chemical compound

Beta blocker

increases_quantity of

drug/chemical compound

Homocitrulline

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49433

drug/chemical compound

Beta blocker

increases_quantity of

drug/chemical compound

Salicylate

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49434

drug/chemical compound

Beta blocker

increases_quantity of

drug/chemical compound

Pyroglutamine

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49435

drug/chemical compound

Beta blocker

increases_quantity of

drug/chemical compound

Hydroxyisovaleroylcarnitine

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49436

drug/chemical compound

Beta blocker

increases_quantity of

drug/chemical compound

2-Methylbutyroylcarnitine

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49437

drug/chemical compound

Beta blocker

decreases_quantity of

drug/chemical compound

Serotonin

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49438

drug/chemical compound

Beta blocker

decreases_quantity of

drug/chemical compound

Dihomo-linoleate

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49440

drug/chemical compound

Beta blocker

decreases_quantity of

drug/chemical compound

10-Nonadecenoate

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49441

drug/chemical compound

Beta blocker

decreases_quantity of

drug/chemical compound

Heptadecanoic acid

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49442

drug/chemical compound

Beta blocker

decreases_quantity of

drug/chemical compound

Eicosenoic acid

in blood serum
Comment For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased.
Formal Description
Interaction-ID: 49445

drug/chemical compound

Beta blocker

decreases_quantity of

drug/chemical compound

(R)-3-Hydroxybutanoate

in blood serum
Comment For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found.
Formal Description
Interaction-ID: 49446

drug/chemical compound

ACE inhibitor

increases_quantity of

gene/protein

His-Trp-Glu-Ser-Ala-Ser-X-X

in blood serum
Comment For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found.
Formal Description
Interaction-ID: 49447

drug/chemical compound

ACE inhibitor

increases_quantity of

gene/protein

des-Arg9-bradykinin

in blood serum
Comment For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found.
Formal Description
Interaction-ID: 49448

drug/chemical compound

ACE inhibitor

decreases_quantity of

drug/chemical compound

Phe-Phe

in blood serum
Comment For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found.
Formal Description
Interaction-ID: 49449

drug/chemical compound

ACE inhibitor

decreases_quantity of

drug/chemical compound

Asp-Phe

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49450

drug/chemical compound

Diuretic

increases_quantity of

drug/chemical compound

Pseudouridine

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49451

drug/chemical compound

Diuretic

increases_quantity of

drug/chemical compound

C-glycosyltryptophan

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49455

drug/chemical compound

Diuretic

increases_quantity of

drug/chemical compound

Glutaroyl carnitine

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49456

drug/chemical compound

Diuretic

increases_quantity of

drug/chemical compound

Urate

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49462

drug/chemical compound

Diuretic

increases_quantity of

drug/chemical compound

Homocitrulline

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49463

drug/chemical compound

Diuretic

increases_quantity of

gene/protein

His-Trp-Glu-Ser-Ala-Ser-X-X

in blood serum
Comment Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively.
Formal Description
Interaction-ID: 49464

drug/chemical compound

Diuretic

decreases_quantity of

drug/chemical compound

Phe-Phe

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49465

drug/chemical compound

Statin

increases_quantity of

drug/chemical compound

LysoPC(20:4)

Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49466

drug/chemical compound

Statin

increases_quantity of

drug/chemical compound

LysoPE(20:4)

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49467

drug/chemical compound

Statin

decreases_quantity of

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49468

drug/chemical compound

Statin

decreases_quantity of

drug/chemical compound

1-Palmitoylglycerophosphoinositol

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49469

drug/chemical compound

Statin

decreases_quantity of

drug/chemical compound

Lathosterol

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49470

drug/chemical compound

Statin

increases_quantity of

drug/chemical compound

Isobutyrylcarnitine

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49471

drug/chemical compound

Statin

increases_quantity of

drug/chemical compound

LysoPC(22:6)

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49472

drug/chemical compound

Statin

increases_quantity of

drug/chemical compound

alpha-Tocopherol

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49473

drug/chemical compound

Statin

decreases_quantity of

drug/chemical compound

Glycochenodeoxycholate

in blood serum
Comment For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased).
Formal Description
Interaction-ID: 49477

drug/chemical compound

Statin

increases_quantity of

drug/chemical compound

Uridine

in blood serum
Drugbank entries Show/Hide entries for
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49478

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

2-Hydroxyisobutyric acid

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49479

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

3-Dehydrocarnitine

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49480

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

Riboflavin

in blood serum
Drugbank entries Show/Hide entries for
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49481

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

Pantothenate

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49482

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

Indolelactate

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49483

drug/chemical compound

Fibrate

decreases_quantity of

drug/chemical compound

Pyroglutamine

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49484

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

Carnitine

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49485

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

Pipecolate

in blood serum
Comment For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive.
Formal Description
Interaction-ID: 49487

drug/chemical compound

Fibrate

increases_quantity of

drug/chemical compound

Uridine

in blood serum
Drugbank entries Show/Hide entries for